Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON: HZN-825 in Diffuse Cutaneous Systemic Sclerosis
jRCT2031220221Phase 2Completed
- Sponsor
- Horizon Therapeutics
- Start
- Jul 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of fipaxalparant in diffuse cutaneous systemic sclerosis (dcSSc) (3 arms), sponsored by Horizon Therapeutics. Primary endpoint: Change in FVC % predicted from Baseline to Week 52. Started Jul 2022; status: completed.
02
Drugs
fipaxalparant
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on jRCT2031220221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220221.